Study reveals an alternate origin of brain mosaicism in some children with focal epilepsy

In most people, every cell in their body contains the same genetic information. However, sometimes people can have two or more genetically different sets of cells.

Orphelia pushes boundaries with regulatory barriers for pediatric indications – Pharmaceutical Technology

Share this article Orphelia has developed Kizfizo as the first oral suspension of temozolomide to treat neuroblastoma. Credit: Nyaaka/Shutterstock.com Orphelia Pharma is taking action to

November 14, 2023

Biotech’s third quarter was relatively bright — with a few caveats

The weather is getting cooler, but biotech’s recovery is heating up. After a years-long wait-and-see game exhausted many industry insiders, recent signals indicate a mostly

October 5, 2024

A preview of Neurocrine’s muscarinic drug readout

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Welcome back!

July 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.